IMI vs Invitae Which Is More Promising?
IMI and Invitae are both companies operating in the healthcare sector, with a focus on genetics and personalized medicine. IMI is a global provider of medical imaging software and services, while Invitae specializes in genetic testing and diagnostics. Both companies have seen significant growth in recent years, with IMI benefiting from increased demand for imaging solutions and Invitae capitalizing on the growing trend towards personalized healthcare. Investors looking to capitalize on the healthcare industry's growth may consider these stocks as potential investment opportunities.
IMI or Invitae?
When comparing IMI and Invitae, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between IMI and Invitae.
Dividend Investors:
Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company.
IMI has a dividend yield of 1.66%, while Invitae has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. IMI reports a 5-year dividend growth of -7.81% year and a payout ratio of 29.10%. On the other hand, Invitae reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.
Value Investors:
Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with IMI P/E ratio at 18.17 and Invitae's P/E ratio at -0.00. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. IMI P/B ratio is 4.21 while Invitae's P/B ratio is -0.00.
Growth Investors:
Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, IMI has seen a 5-year revenue growth of 0.20%, while Invitae's is 0.00%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with IMI's ROE at 23.85% and Invitae's ROE at 472.72%.
Retail Investors:
Retail investors often consider stock affordability and company familiarity. For example, day low prices are £1753.00 for IMI and $0.00 for Invitae. Over the past year, IMI's prices ranged from £1512.00 to £1911.00, with a yearly change of 26.39%. Invitae's prices fluctuated between $0.00 and $1.66, with a yearly change of 331820.00%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.